Screener
R&D at other companies
Where this comes from
Reported directly by First Tracks Biotherapeutics Inc in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: First Tracks Biotherapeutics Inc’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224190
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $33,955 | $41,465 |
| General and administrative | 18,856 | 9,815 |
| Total operating expenses | 52,811 | 51,280 |
| Loss from operations | (52,811) | (51,280) |
| Other income (expense), net: | ||
| Interest income | 2,328 | 4,091 |
| Other expense, net | (1) | (7) |
Item 1. Combined Financial Statements.
FAQ
- What is First Tracks Biotherapeutics Inc's R&D?
- First Tracks Biotherapeutics Inc (TRAX) reported R&D of $33.96M in Q1 2026.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about First Tracks Biotherapeutics Inc's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude